Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1995;73(5):631–642.

Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.

F O ter Kuile 1, F Nosten 1, C Luxemburger 1, D Kyle 1, P Teja-Isavatharm 1, L Phaipun 1, R Price 1, T Chongsuphajaisiddhi 1, N J White 1
PMCID: PMC2486817  PMID: 8846489

Abstract

Between 1990 and 1994, a series of prospective studies were conducted to optimize the treatment of multidrug-resistant falciparum malaria on the borders of Thailand. The tolerance of various treatment regimens containing either mefloquine 15 mg/kg (M15) or 25 mg/kg (M25) was evaluated in 3673 patients aged between 6 months and 88 years. Early vomiting (within 1 hour) is an important determinant of treatment outcome in these areas, despite re-administration of the dose. Overall, 7 % of the patients vomited within an hour. Significant risk factors were age < or = 6 years (relative risk (RR), 3.9) or > or 50 years (RR, 2.7), the higher mefloquine dose (M25) (RRm 2.7), vomiting < 24 hours before enrolment (RR, 2.5), axillary temperature > 38.0 degrees C (RR, 1.6), and parasitaemia > 10,000/microliter (RR, 1.3). In children < or = 2 years, 30% vomited with M25, and 13% did not tolerate a repeat dose. Vomiting was reduced 40% by splitting the higher dose (RR, 0.6; 95% CI, 0.4-0.8), and 50% by giving mefloquine on the second day in combination with artesunate (RR, 0.5; CI, 0.3-0.9). Anorexia, nausea, vomiting, dizziness, and sleeping disorders were 1.1-1.4 times more frequent with M25 than M15 in the three days following treatment, but were similar in the single or split-dose M25 groups, despite twofold higher mefloquine concentrations obtained with the latter. There was no evidence that diarrhoea, headache, and abdominal pain were associated with mefloquine use. High-dose mefloquine is well tolerated but should be given as a split dose.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boudreau E. F., Fleckenstein L., Pang L. W., Childs G. E., Schroeder A. C., Ratnaratorn B., Phintuyothin P. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin Pharmacol Ther. 1990 Oct;48(4):399–409. doi: 10.1038/clpt.1990.168. [DOI] [PubMed] [Google Scholar]
  2. Chongsuphajaisiddhi T., Sabchareon A., Chantavanich P., Singhasivanon V., Attanath P., Wernsdorfer W. H., Sheth U. K. A phase-III clinical trial of mefloquine in children with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1987;65(2):223–226. [PMC free article] [PubMed] [Google Scholar]
  3. Doberstyn E. B., Phintuyothin P., Noeypatimanondh S., Teerakiartkamjorn C. Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine. Bull World Health Organ. 1979;57(2):275–279. [PMC free article] [PubMed] [Google Scholar]
  4. Edstein M. D., Lika I. D., Chongsuphajaisiddhi T., Sabchareon A., Webster H. K. Quantitation of Fansimef components (mefloquine + sulfadoxine + pyrimethamine) in human plasma by two high-performance liquid chromatographic methods. Ther Drug Monit. 1991 Mar;13(2):146–151. doi: 10.1097/00007691-199103000-00010. [DOI] [PubMed] [Google Scholar]
  5. Fontanet A. L., Walker A. M. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am J Trop Med Hyg. 1993 Oct;49(4):465–472. doi: 10.4269/ajtmh.1993.49.465. [DOI] [PubMed] [Google Scholar]
  6. Hall A. P., Doberstyn E. B., Karnchanachetanee C., Samransamruajkit S., Laixuthai B., Pearlman E. J., Lampe R. M., Miller C. F., Phintuyothin P. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. Br Med J. 1977 Jun 25;1(6077):1626–1628. doi: 10.1136/bmj.1.6077.1626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harinasuta T., Bunnag D., Lasserre R., Leimer R., Vinijanont S. Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. Lancet. 1985 Apr 20;1(8434):885–888. doi: 10.1016/s0140-6736(85)91670-8. [DOI] [PubMed] [Google Scholar]
  8. Harinasuta T., Bunnag D., Wernsdorfer W. H. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983;61(2):299–305. [PMC free article] [PubMed] [Google Scholar]
  9. Karbwang J., Bangchang K. N., Bunnag D., Harinasuta T. Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. Bull World Health Organ. 1991;69(2):207–212. [PMC free article] [PubMed] [Google Scholar]
  10. Karbwang J., Looareesuwan S., Phillips R. E., Wattanagoon Y., Molyneux M. E., Nagachinta B., Back D. J., Warrell D. A. Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. Br J Clin Pharmacol. 1987 Apr;23(4):477–481. doi: 10.1111/j.1365-2125.1987.tb03079.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Karbwang J., Na-Bangchang K., Thanavibul A., Bunnag D., Chongsuphajaisiddhi T., Harinasuta T. Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria. Bull World Health Organ. 1994;72(2):233–238. [PMC free article] [PubMed] [Google Scholar]
  12. Karbwang J., White N. J. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990 Oct;19(4):264–279. doi: 10.2165/00003088-199019040-00002. [DOI] [PubMed] [Google Scholar]
  13. Kofi Ekue J. M., Ulrich A. M., Rwabwogo-Atenyi J., Sheth U. K. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ. 1983;61(4):713–718. [PMC free article] [PubMed] [Google Scholar]
  14. Laothavorn P., Karbwang J., Na Bangchang K., Bunnag D., Harinasuta T. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast Asian J Trop Med Public Health. 1992 Mar;23(1):51–54. [PubMed] [Google Scholar]
  15. Luxemburger C., ter Kuile F. O., Nosten F., Dolan G., Bradol J. H., Phaipun L., Chongsuphajaisiddhi T., White N. J. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):213–217. doi: 10.1016/0035-9203(94)90303-4. [DOI] [PubMed] [Google Scholar]
  16. Nosten F., Luxemburger C., ter Kuile F. O., Woodrow C., Eh J. P., Chongsuphajaisiddhi T., White N. J. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 1994 Oct;170(4):971–977. doi: 10.1093/infdis/170.4.971. [DOI] [PubMed] [Google Scholar]
  17. Nosten F., ter Kuile F. O., Luxemburger C., Woodrow C., Kyle D. E., Chongsuphajaisiddhi T., White N. J. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993 Apr 24;341(8852):1054–1056. doi: 10.1016/0140-6736(93)92412-m. [DOI] [PubMed] [Google Scholar]
  18. Nosten F., ter Kuile F., Chongsuphajaisiddhi T., Luxemburger C., Webster H. K., Edstein M., Phaipun L., Thew K. L., White N. J. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991 May 11;337(8750):1140–1143. doi: 10.1016/0140-6736(91)92798-7. [DOI] [PubMed] [Google Scholar]
  19. Palmer K. J., Holliday S. M., Brogden R. N. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993 Mar;45(3):430–475. doi: 10.2165/00003495-199345030-00009. [DOI] [PubMed] [Google Scholar]
  20. Slutsker L. M., Khoromana C. O., Payne D., Allen C. R., Wirima J. J., Heymann D. L., Patchen L., Steketee R. W. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ. 1990;68(1):53–59. [PMC free article] [PubMed] [Google Scholar]
  21. Smithuis F. M., van Woensel J. B., Nordlander E., Vantha W. S., ter Kuile F. O. Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother. 1993 Sep;37(9):1977–1981. doi: 10.1128/aac.37.9.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Steffen R., Fuchs E., Schildknecht J., Naef U., Funk M., Schlagenhauf P., Phillips-Howard P., Nevill C., Stürchler D. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 1993 May 22;341(8856):1299–1303. doi: 10.1016/0140-6736(93)90814-w. [DOI] [PubMed] [Google Scholar]
  23. ter Kuile F. O., Nosten F., Thieren M., Luxemburger C., Edstein M. D., Chongsuphajaisiddhi T., Phaipun L., Webster H. K., White N. J. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992 Dec;166(6):1393–1400. doi: 10.1093/infdis/166.6.1393. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES